Dosing Frequency Shapes Adherence in Older Psoriasis Patients

Dermatology Times has turned its attention to a cohort that trials often underrepresent: older patients with psoriasis who must reconcile access limits, adherence demands and dosing frequency in daily practice. The discussion centers on a familiar triangle of trade-offs. What the coverage does not supply, however, is the trial-grade evidence readers may expect — a caveat that shapes everything below.

The piece frames the problem around three linked variables. Access determines whether a patient reaches a therapy at all. Adherence determines whether that therapy can work. Dosing frequency sits at the intersection, because regimens that demand more of an aging patient tend to fail more often outside the controlled setting of a clinical trial.

Psoriasis (a chronic immune-mediated skin disease marked by scaly, well-demarcated plaques) already tests adherence in younger populations. Older patients add competing comorbidities, polypharmacy and, frequently, fixed incomes. A once-daily topical is a different proposition for a 75-year-old managing five other medications than for a trial enrollee of 40.

Why does dosing frequency matter more with age?

The logic is mechanical rather than mysterious. Each additional administration per day multiplies the opportunities for a missed dose. For older patients, that arithmetic collides with visual impairment, dexterity limits and caregiver dependence. Less frequent dosing, by extension, reduces the failure surface.

The Dermatology Times coverage invites clinicians to weigh this variable at the point of prescribing, not merely to observe it at follow-up. That is the practical thrust of the piece: the prescription is where adherence is won or lost.

What stands between older patients and therapy?

Access, the first leg of the triangle, receives the sharpest scrutiny. Coverage decisions, prior authorization requirements and cost-sharing structures all filter which therapies an older patient can realistically sustain. A therapy that a patient cannot obtain consistently is, in adherence terms, indistinguishable from a therapy the patient abandons.

The coverage does not quantify these barriers. No copayment figures, approval rates or formulary specifics appear in the piece. Readers should therefore treat its access argument as a framing of a documented problem, not as new measurement.

What the piece leaves unanswered

This is where skepticism is warranted. The article names its three variables — access, adherence, dosing frequency — but, as presented here, it supplies no effect sizes, no cohort size, no study design and no comparator. There is no PASI score (Psoriasis Area and Severity Index, the standard 0–72 measure of plaque burden) and no adherence percentage to anchor the claims.

That absence does not make the argument wrong. The association between dosing frequency and adherence is among the more replicated findings in chronic dermatology care. It does mean the piece functions as a clinical commentary rather than as evidence, and clinicians should read it accordingly.

The prescribing takeaway

For dermatologists managing older psoriasis patients, the actionable residue is a prescribing habit: prefer the least frequent dosing the evidence supports, verify that the patient's coverage actually permits it, and revisit both assumptions at each visit. Access that lapses mid-course erodes adherence as surely as a burdensome regimen does.

Whether manufacturers respond with formulations tuned to this cohort — longer intervals, simpler administration — will determine whether this commentary ages into a solved problem or remains a standing caution.